inclusion criteria: 1. positive for sars-cov-2 antigen via nasal swab at or within the past 24 hours of the screening visit detected using an fda authorized sars-cov-2 antigen test. 2. onset of signs and symptoms consistent with covid-19\* no longer than within the past 3 days\* and have either a) a fever of at least 100 °f or b) at least two moderate or severe symptoms (cough, sore throat, nasal congestion, headache, chills/sweats, muscle or joint pain, fatigue, and nausea) at the time of screening. 3. provides written informed consent prior to initiation of any study procedures. 4. be able to understand and agrees to comply with planned study procedures and be available for all study visits. 5. agrees to the collection of nasopharyngeal swabs, oropharyngeal swabs, oral saliva specimen collection and venous blood specimens per protocol. 6. agrees to refrain from using oral antiseptics (e.g. hydrogen peroxide rinse, listerine) or mouthwashes of any kind during the study. 7. male or non-pregnant female, 18 to 65 years of age, inclusive, at time of enrollment. 8. no uncontrolled disease process (chronic or acute), other than covid-19 signs and symptoms\*. 9. no physical or mental conditions or attributes at the time of screening, which in the opinion of the pi, will prevent full adherence to, and completion of, the protocol.

inclusion criteria: 1. positive for sars-cov-2 antigen via nasal swab at or within the past 24 hours of the screening visit detected using an fda authorized sars-cov-2 antigen test. 2. onset of signs and symptoms consistent with covid-19\* no longer than within the past 3 days\* and have either a) a fever of at least 100 °f or b) at least two moderate or severe symptoms (cough, sore throat, nasal congestion, headache, chills/sweats, muscle or joint pain, fatigue, and nausea) at the time of screening. 3. provides written informed consent prior to initiation of any study procedures. 4. be able to understand and agrees to comply with planned study procedures and be available for all study visits. 5. agrees to the collection of nasopharyngeal swabs, oropharyngeal swabs, oral saliva specimen collection and venous blood specimens per protocol. 6. agrees to refrain from using oral antiseptics (e.g. hydrogen peroxide rinse, listerine) or mouthwashes of any kind during the study. 7. male or non-pregnant female, 18 to 65 years of age, inclusive, at time of enrollment. 8. no uncontrolled disease process (chronic or acute), other than covid-19 signs and symptoms\*. 9. no physical or mental conditions or attributes at the time of screening, which in the opinion of the pi, will prevent full adherence to, and completion of, the protocol.

inclusion criteria: positive for sars-cov-2 antigen via nasal swab at or within the past 24 hours of the screening visit detected using an fda authorized sars-cov-2 antigen test. onset of signs and symptoms consistent with covid-19* no longer than within the past 3 days* and have either a) a fever of at least 100 °f or b) at least two moderate or severe symptoms (cough, sore throat, nasal congestion, headache, chills/sweats, muscle or joint pain, fatigue, and nausea) at the time of screening. provides written informed consent prior to initiation of any study procedures. be able to understand and agrees to comply with planned study procedures and be available for all study visits. agrees to the collection of nasopharyngeal swabs, oropharyngeal swabs, oral saliva specimen collection and venous blood specimens per protocol. agrees to refrain from using oral antiseptics (e.g. hydrogen peroxide rinse, listerine) or mouthwashes of any kind during the study. male or non-pregnant female, 18 to 65 years of age, inclusive, at time of enrollment. no uncontrolled disease process (chronic or acute), other than covid-19 signs and symptoms*. no physical or mental conditions or attributes at the time of screening, which in the opinion of the pi, will prevent full adherence to, and completion of, the protocol.

inclusion criteria: positive for sars-cov-2 antigen via nasal swab at or within the past 24 hours of the screening visit detected using an fda authorized sars-cov-2 antigen test. onset of signs and symptoms consistent with covid-19* no longer than within the past 3 days* and have either a) a fever of at least 100 °f or b) at least two moderate or severe symptoms (cough, sore throat, nasal congestion, headache, chills/sweats, muscle or joint pain, fatigue, and nausea) at the time of screening. provides written informed consent prior to initiation of any study procedures. be able to understand and agrees to comply with planned study procedures and be available for all study visits. agrees to the collection of nasopharyngeal swabs, oropharyngeal swabs, oral saliva specimen collection and venous blood specimens per protocol. agrees to refrain from using oral antiseptics (e.g. hydrogen peroxide rinse, listerine) or mouthwashes of any kind during the study. male or non-pregnant female, 18 to 65 years of age, inclusive, at time of enrollment. no uncontrolled disease process (chronic or acute), other than covid-19 signs and symptoms*. no physical or mental conditions or attributes at the time of screening, which in the opinion of the pi, will prevent full adherence to, and completion of, the protocol.

inclusion criteria: 1. positive for sars-cov-2 antigen via nasal swab at or within the past 24 hours of the screening visit detected using an fda authorized sars-cov-2 antigen test. 2. onset of signs and symptoms consistent with covid-19* no longer than within the past 3 days* and have either a) a fever of at least 100 °f or b) at least two moderate or severe symptoms (cough, sore throat, nasal congestion, headache, chills/sweats, muscle or joint pain, fatigue, and nausea) at the time of screening. 3. provides written informed consent prior to initiation of any study procedures. 4. be able to understand and agrees to comply with planned study procedures and be available for all study visits. 5. agrees to the collection of nasopharyngeal swabs, oropharyngeal swabs, oral saliva specimen collection and venous blood specimens per protocol. 6. agrees to refrain from using oral antiseptics (e.g. hydrogen peroxide rinse, listerine) or mouthwashes of any kind during the study. 7. male or non-pregnant female, 18 to 65 years of age, inclusive, at time of enrollment. 8. no uncontrolled disease process (chronic or acute), other than covid-19 signs and symptoms*. 9. no physical or mental conditions or attributes at the time of screening, which in the opinion of the pi, will prevent full adherence to, and completion of, the protocol.

inclusion criteria: 1. positive for sars-cov-2 antigen via nasal swab at or within the past 24 hours of the screening visit detected using an fda authorized sars-cov-2 antigen test. 2. onset of signs and symptoms consistent with covid-19* no longer than within the past 3 days* and have either a) a fever of at least 100 °f or b) at least two moderate or severe symptoms (cough, sore throat, nasal congestion, headache, chills/sweats, muscle or joint pain, fatigue, and nausea) at the time of screening. 3. provides written informed consent prior to initiation of any study procedures. 4. be able to understand and agrees to comply with planned study procedures and be available for all study visits. 5. agrees to the collection of nasopharyngeal swabs, oropharyngeal swabs, oral saliva specimen collection and venous blood specimens per protocol. 6. agrees to refrain from using oral antiseptics (e.g. hydrogen peroxide rinse, listerine) or mouthwashes of any kind during the study. 7. male or non-pregnant female, 18 to 65 years of age, inclusive, at time of enrollment. 8. no uncontrolled disease process (chronic or acute), other than covid-19 signs and symptoms*. 9. no physical or mental conditions or attributes at the time of screening, which in the opinion of the pi, will prevent full adherence to, and completion of, the protocol.